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As a Junior Resident from an American Institution
(Department of Surgery at Yale University School of
Medicine) under the sponsorship of Dr Irvin Modlin, I had
the opportunity to attend the Department of Endocrine
Surgery at the Hospital of ‘G.B. Rossi’ of the University of
Verona as a visiting Fellow for 2 years. Headed by Professor
Paolo Pederzoli, who is the president of the Italian
Association of the Study of the Pancreas (AISP), I worked
under Assistant Professor Claudio Bassi who is a member of
the Executive Committee of the International Association
of Pancreatology and the International Hepato Pancreato
Biliary Association (Figure 1). The automonous Division of
Pancreatic Surgery of the Department of Surgical Sciences
and Gastroenterology comprises 16 doctors, of whom 10 are
residents and one is working towards a PhD. This service is
the Italian reference centre for diseases of the pancreas and
the Italian coordinator for multiple multi-centre national
and international clinical trials [1].
The service admits 650 patients affected with pancre-
atic pathology per year. The number of patients with
pancreatic neoplasia who require staging, inpatient pain
management, outpatient medical treatment, surgical
treatment or consultations at outside institutions is about
1000 per year. Sixty-eight percent of all admitted patients
undergo a surgical procedure. Each year about 130 major
pancreatic resections (duodenopancreatectomies, distal
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Figure 1. Department of Endocrine Surgery at the ‘G.B. Rossi’ Hospital of the University of Verona. Seated from right to left: Massimo Falconi, MD; Paolo Pederzoli,
MD; Claudio Bassi, MD; Hazem Abbas, MD. Standing from right to left, first row: Francesco Nacchia, MD; Isabella Frigerio, MD; Federica Damini, MD; Rosella Bettini,
MD; Manuela Sargenti, MD;Valeria Parisi, MD. Standing from right to left, back row: Giuseppe Mascetta, MD;William Mantovani, MD. Not on photo: Roberto Salvia,
MD and Giovanni Butturini, MD.
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pancreatectomies and total pancreatectomies) are per-
formed (also in the laparoscopic setting). The number of
pancreatic operations averages four per week. The activity of
the Outpatient Clinic accounts for about 250 admissions an-
nually. Based on an allotment of 20 beds, the index of occu-
pation is 121% and the mean hospital stay is 9.8 days. The
DRG is 2.62. The extra-regional attraction index is 81%.
Scientific research is performed in strict collaboration
with the Gastroenterology, Radiological, Pathological
(which contains Molecular Biology), Oncological, Intens-
ive Care and Pharmacological Departments, making the
total number of participating doctors and researchers about
100. This multidisciplinary approach has led not only to
numerous clinical research projects on new diagnostic and
therapeutic techniques, but also to projects in molecular
biology and genetics. Specifically, Professor Giusseppe
Zamboni of the Pathology Department’s work on mucinous
cystic tumours has recently led to the new World Health
Organization Histopathological Classification of Mucinous
Tumours of the Pancreas [2,3]. Professor Carlo Procacci of
the Radiological Department has published numerous
articles on the diagnostic differentiation of pancreatic cystic
lesions and has defined the role of CT in blunt trauma to
the pancreas [4–12]. Professor Giorgio Cavallini of the
Department of Gastroenterology has focused on the role of
pharmacological prevention of acute pancreatitis during
ERCP [13], and in collaboration with Professor Giorgio
Talamini on the understanding of risk factors in pancreati-
tis and factors that affect quality of life in these patients
[14,15]. Professor Aldo Scarpa of the Molecular Biology
Division has helped to characterise the genetic events lead-
ing to pancreatic oncogenesis [16,22]. During my time in
his laboratory I had the opportunity to principally work
with pancreatic endocrine tumours (PETs). Benefiting from
large frozen tissue banks of these rare tumours, I studied dif-
fering levels of gene expression of PETs compared with nor-
mal islet cells and pancreatic adenocarcinoma cell lines. I
learned multiple modern molecular biological techniques
including real-time PCR, cDNA-amplified fragment length
polymorphisms and microarrays.
Clinical research on surgical issues initially focused on
antibiotic pharmacokinetics within the pancreas and the
role of intraperitoneal lavage and necrosectomy therapy in
infected pancreatic necrosis and pancreatic abscess [23–27].
The clinical impact of antibiotic prophylaxis in severe pan-
creatitis has been tested in two clinical trials [28,29]. The
efficacy of octreotide and surgical intervention in the
management of pancreatic fistulas was analysed [30–33].
The utility of chemoembolisation for synchronous hepatic
metastases of pancreatic endocrine tumours was reported
[34]. The vast experience with intraductal papillary mucin-
ous tumours has been published recently [35,36]. Current
projects include an examination of the feasibility and
benefits of robot-assisted laparoscopic pancreatic resections,
cellular motility in pancreatic adenocarcinoma and micro-
array analysis of tumour samples. Aside from my clinical
duties, I reviewed the clinical experience with mucinous
cystadenocarcinomas and studied the ability of tumour
markers to determine invasion and prognosis in these
tumours and the utility of tumour markers in differentiating
mucinous cystic tumours from serous cystic tumours. I also
participated in an international multi-centre trial examin-
ing the utility of procalcitonin in managing necrotising
pancreatitis and peritonitis.
The didactic component of the Pancreatic Unit is not
secondary. This is especially true with regard to the resi-
dents in general surgery, who in the course of 6 years of
residency, are trained to perform all major pancreatic resec-
tions on their own. Each week there is one lecture given by
residents and another given by the staff on a topic relating
to HPB pathology. There is a weekly interdepartmental
meeting, in which the following week’s cases are presented
and discussed by all of the departments. Morbidity and
mortality conferences are held monthly.
The strength of the Endocrine and Pancreatic Unit at
the University of Verona lies in its multidisciplinary
approach to diseases of the pancreas. The centre at ‘G.B.
Rossi’ Hospital contains leaders in their respective fields,
and the atmosphere of such a large team of physicians inter-
ested in the pancreas has created a unit that is not only the
national referral centre for pancreatic pathologies, but also
an internationally renowned centre attracting patients and
physicians from around the world.
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